Alpha-Lipoic Acid: Does It Really Improve Insulin Resistance?

A look at what the trials actually show about this antioxidant and blood sugar control.

Track the foods that fit your goals. Track it free with Ration →

By the Ration Editorial Team · Reviewed against primary research · Updated July 13, 2026

Alpha-lipoic acid is a compound made naturally inside mitochondria, the energy-producing structures in cells.

It acts as a cofactor for enzymes involved in energy metabolism.

It is also a antioxidant, meaning it can neutralize reactive oxygen species and help regenerate other antioxidants like glutathione and vitamin C.

Small amounts occur in foods such as red meat, organ meats, broccoli, spinach, and tomatoes. Supplemental doses are far higher than what diet alone provides.

Researchers think alpha-lipoic acid may influence glucose metabolism through a few overlapping mechanisms.

• Reducing oxidative stress in cells, which is thought to interfere with insulin signaling^[8]
• Supporting mitochondrial function in fat and muscle tissue, where insulin resistance often originates^[9]
• Modulating inflammatory signaling pathways, including toll-like receptor 2 (TLR2) activity linked to insulin resistance^[10]
• Possibly improving glutathione peroxidase activity, an internal antioxidant enzyme^[11]

These mechanisms are plausible but mostly come from animal or cell studies, so they explain a hypothesis more than they prove an effect in people.

The clearest signal in human trials is a reduction in HOMA-IR, a calculated index of insulin resistance based on fasting glucose and insulin.

• ↓HOMA-IRAHuman trials

  Research may lower HOMA-IR · strong agreement · 6 studies

  View 5 studies on PubMed

  • Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis (2025)
  • Effect of alpha-lipoic acid on blood glucose, insulin resistance and glutathione peroxidase of type 2 diabetic patients (2011)
  • Beneficial effects of pioglitazone and α-lipoic acid in patients with polycystic ovaries syndrome (2023)
  • Familial diabetes predisposes PCOS patients to insulin resistance (IR), reproductive impairment and hepatic dysfunction: effects of d-chiro inositol (DCI) and alpha lipoic acid (ALA) administration on hepatic insulin extraction (HIE) index (2022)
  • The effect of alpha-lipoic acid supplementation on anthropometric, glycemic, lipid, oxidative stress, and hormonal parameters in individuals with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials (2024)
• ↑Insulin SensitivityDPreliminary

  Research may raise Insulin Sensitivity · strong agreement · 6 studies

  View 5 studies on PubMed

  • Nutritional Supplements and Complementary Therapies in Polycystic Ovary Syndrome (2022)
  • Effects of alpha lipoic acid on metabolic syndrome: A comprehensive review (2022)
  • Alpha Lipoic Acid Efficacy in PCOS Treatment: What Is the Truth? (2023)
  • Alpha-Lipoic Acid and Glucose Metabolism: A Comprehensive Update on Biochemical and Therapeutic Features (2022)
  • Htd2 deficiency-associated suppression of α-lipoic acid production provokes mitochondrial dysfunction and insulin resistance in adipocytes (2021)

A 2025 systematic review and meta-analysis in overweight or obese adults found alpha-lipoic acid supplementation improved several intermediate disease markers, including measures related to insulin resistance^[1].

Multiple meta-analyses in women with polycystic ovary syndrome (PCOS) report similar improvements in glycemic and insulin-related markers, though effect sizes vary by trial quality and dose^[2][3].

One trial combining alpha-lipoic acid with pioglitazone found improvements in metabolic parameters in PCOS, though it is hard to isolate ALA's individual contribution in a combination therapy^[4].

A broader review of nutritional supplements in PCOS lists alpha-lipoic acid among options with modest supportive evidence, alongside inositol and vitamin D^[5].

In older type 2 diabetes trials, alpha-lipoic acid supplementation was linked to reduced fasting blood glucose and improved HOMA-IR alongside increases in glutathione peroxidase^[11][12].

A comprehensive review of alpha-lipoic acid in metabolic syndrome similarly points to consistent HOMA-IR improvements across studies, graded as a fairly strong body of evidence^[6].

Where the picture gets murkier is insulin sensitivity itself, meaning how efficiently cells respond to a given amount of insulin. Despite six sources looking at this outcome, the consensus direction trends toward improvement but the evidence grade is weak, reflecting inconsistent trial designs, small sample sizes, and mixed statistical significance.

One study in PCOS patients with a family history of diabetes found that alpha-lipoic acid combined with d-chiro-inositol affected hepatic insulin extraction, a more specific marker of liver insulin handling, but results were nuanced rather than a clean win for insulin sensitivity broadly^[7].

• People with type 2 diabetes, where early trials measured fasting glucose, HOMA-IR, and oxidative stress markers^[11][12]
• Women with PCOS, where insulin resistance is a common underlying feature^[2][3][4][7]
• Adults with overweight or obesity, assessed for broader metabolic markers^[1]
• People with metabolic syndrome more generally^[6]

It has not been well studied in people without any metabolic risk factors, so extrapolating benefits to healthy, lean individuals is not well supported.

Trial doses have ranged widely, commonly somewhere between 300 mg and 1,200 mg per day, taken orally, often split into two doses.

Duration in most trials ran from 8 to 12 weeks, which limits what we know about longer-term use.

There is no established consensus dose for insulin resistance specifically, and higher doses have not clearly outperformed lower ones across studies.

Alpha-lipoic acid is generally well tolerated in the doses used in these trials.

• Mild gastrointestinal upset, such as nausea or stomach discomfort
• Skin rash in rare cases
• Theoretical risk of low blood sugar when combined with other glucose-lowering approaches, since it may have an additive effect^[8][11]

People already managing diabetes or taking glucose-lowering medications should be especially mindful of this, since the combined effect on blood sugar is not fully mapped out in long-term safety data.

Safety in pregnancy, and over periods longer than a few months, has not been well studied.

The most consistent finding across trials and meta-analyses is that alpha-lipoic acid supplementation tends to lower HOMA-IR, a marker of insulin resistance, in people with metabolic conditions like PCOS, type 2 diabetes, or obesity^{[1][2][6][11][12]}.

Whether it meaningfully improves insulin sensitivity itself, the more direct physiological outcome, is far less certain given the weak and inconsistent evidence grade on that specific measure.

People interested in this compound for metabolic health should treat it as a supplement with promising but incomplete evidence, not a settled solution.